🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Eltrombopag Induced Liver Dysfunction During Treatment of Immunethrombocytopenic Purpura

RecruitingNAAges 18 Years - 75 YearsAllSohag University
NCT07093606 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

this study amis to assess the incidence and severity of liver dysfunction in ITP patients receiving eltrombopag.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria Adult patients (≥18 years) diagnosed with primary ITP. Receiving eltrombopag as part of their treatment. Baseline liver function tests (LFTs) within normal limits. Patients with diabetes Patients without diabetes Patients with fatty liver Patients without fatty liver Exclusion Criteria: Pre-existing liver disease (e.g., hepatitis, cirrhosis, NAFLD). Concurrent use of hepatotoxic drugs. Patients lost to follow-up.
💊

What it tests

  • Eltrombopag
📍

Where

1 site
Sohag university hospital
Sohag, Egypt
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy